Quantbot Technologies LP Has $3.24 Million Stock Holdings in DexCom, Inc. $DXCM

Key Points

• Quantbot Technologies LP has significantly increased its stake in DexCom, Inc. by 136.9% in the first quarter, owning 47,390 shares valued at approximately $3.24 million.
• Several large investors have also added to their holdings in DexCom, with institutional investors now owning 97.75% of the company’s stock.
• DexCom recently reported earnings of $0.48 per share, exceeding analyst estimates, and expected to post earnings of 2.03 EPS for the current fiscal year.

Quantbot Technologies LP raised its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 136.9% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 47,390 shares of the medical device company's stock after acquiring an additional 27,388 shares during the period. Quantbot Technologies LP's holdings in DexCom were worth $3,236,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Golden State Wealth Management LLC boosted its stake in DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after acquiring an additional 264 shares during the period. Zions Bancorporation National Association UT acquired a new position in DexCom in the first quarter valued at approximately $27,000. Optiver Holding B.V. acquired a new position in DexCom in the fourth quarter valued at approximately $33,000. Heck Capital Advisors LLC acquired a new position in DexCom in the fourth quarter valued at approximately $38,000. Finally, Alpine Bank Wealth Management acquired a new position in DexCom in the first quarter valued at approximately $40,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Price Performance

Shares of NASDAQ DXCM traded up $1.64 during trading on Friday, hitting $82.26. The company had a trading volume of 3,666,928 shares, compared to its average volume of 4,009,486. The company has a market cap of $32.26 billion, a P/E ratio of 57.13, a PEG ratio of 1.69 and a beta of 1.43. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $93.25. The business's 50-day moving average is $82.81 and its 200 day moving average is $79.89. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.03. The company had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The firm's revenue was up 15.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. Equities research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Buying and Selling

In other DexCom news, EVP Sadie Stern sold 6,184 shares of the business's stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total transaction of $526,320.24. Following the sale, the executive vice president directly owned 109,621 shares of the company's stock, valued at $9,329,843.31. The trade was a 5.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Mark G. Foletta sold 2,750 shares of the business's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $81.06, for a total transaction of $222,915.00. Following the sale, the director directly owned 51,121 shares in the company, valued at approximately $4,143,868.26. This trade represents a 5.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 21,906 shares of company stock worth $1,832,451 over the last three months. Corporate insiders own 0.32% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on DXCM. William Blair upgraded DexCom to a "strong-buy" rating in a research report on Thursday, July 31st. Mizuho boosted their price objective on DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 16th. Raymond James Financial boosted their price objective on DexCom from $99.00 to $102.00 and gave the stock a "strong-buy" rating in a research report on Thursday, July 31st. Canaccord Genuity Group reiterated a "buy" rating and set a $106.00 price objective on shares of DexCom in a research report on Friday, August 1st. Finally, Citigroup reiterated a "buy" rating and set a $102.00 price objective (up from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $99.90.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.